CNTNAP1 and chronic inflammatory demyelinating polyradiculoneuropathy: Several studies have shown that anti‐CNTN1 IgG4 antibody‐associated nodopathy accounted for 1%–8% of CIDP cohorts [4, 6, 8, 12, 16, 21, 22], whereas anti‐NF155 IgG4 antibody‐associated nodopathy accounted for 1%–18% [6, 8, 12, 17, 22, 23, 24, 25, 26, 27, 28], and anti‐Caspr1 IgG4 antibody‐associated nodopathy accounted for 0.2%–0.9% [4, 6, 7, 8, 16, 21, 22].